zofran and glp 1 TrimRX *These statements have not been evaluated by the Food and Drug Administration (FDA) Managing GLP-1 Nausea: Complete Guide

Like Semaglutide, Tirzepatide can cause gastrointestinal side effects, especially when beginning treatment or increasing dosage

While the early findings are exciting, these therapies should not be prescribed based on brain health claims alone

The current evidence suggests that GLP-1 RAs should be considered as part of a comprehensive obesity management strategy for adolescents who meet specific criteria, including failure of lifestyle interventions, presence of comorbidities, and adequate support systems

Trends in first-time prescribing First-time prescribing rates (first-time GLP-1 RA prescriptions per total prescriptions) in December 2025 decreased, relative to September 2025 (-6.6%)

Nonetheless, the consistency of findings across multiple studies has generated considerable scientific interest and ongoing clinical trials are investigating this potential therapeutic application more rigorously